Parabolic Drugs financials at a glance
| Year | Year | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rev. | Revenue |
|
6.20B | 9.24B | 7.67B | 4.38B | 2.32B | 768.35M | 749.01M | 731.57M | 188.80M | 0.20M | 0.00M | 0.00M |
| GM % | Gross Margin % |
|
23.73% | 21.98% | -3.49% | 9.31% | -10.34% | 0.00% | -24.15% | 12.70% | -5.88% | 100.00% | 0.00% | 0.00% |
| OM | Operating Margin |
|
15.20% | 13.70% | -17.06% | -15.32% | -65.60% | 0.00% | -132.99% | -69.00% | -193.17% | 0.00% | 0.00% | 0.00% |
| EPS | Earnings Per Share |
|
0.00 | 0.00 | ||||||||||
| Div. | Dividends |
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PR % | Payout Ratio % |
|
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sha. | Shares |
|
61.89m | 61.89m | 61.89m | 61.89m | 61.89m | 61.89m | 61.89m | 61.89m | 61.89m | 61.89m | 61.89m | 61.89m |
| OCF | Operating Cash Flow |
|
23.36M | 2.08B | -1191.09M | 307.49M | -34.47M | 896.60M | 32.31M | 30.67M | 0.00M | 0.00M | 0.00M | 0.00M |
| FCF | Free Cash Flow |
|
-1114.27M | 966.17M | -1624.45M | 54.58M | -163.46M | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| FCFS | Free Cash Flow Per Share |
|
-19.87 | 15.61 | -26.25 | 0.88 | -2.64 | 14.49 | 0.52 | 0.50 | 0.00 | 0.00 | 0.00 | 0.00 |